Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort
Cloxacillin
Cefazolin
Infective Endocarditis
DOI:
10.1016/j.ijid.2023.10.019
Publication Date:
2023-11-04T06:42:27Z
AUTHORS (414)
ABSTRACT
Objective: The aim of this study was to assess the real use cefazolin for methicillin-susceptible S. aureus (MSSA) infective endocarditis (IE) in Spanish National Endocarditis Database (GAMES) and compare it with antistaphylococcal penicillins (ASP).Methods: Prospective cohort retrospective analysis a MSSA IE treated cloxacillin and/or cefazolin. Outcomes assessed were: relapse; intra-hospital, overall endocarditis-related mortality; adverse events. Risk renal toxicity each treatment evaluated separately.Results: We included 631 episodes caused by Antibiotic cloxacillin, or both 537(85%), 57(9%) 37(6%) respectively. Patients had significantly higher rates comorbidities (median Charlson Index 7, p<0.01) previous failure (57.9%, p<0.01). presented septic shock (25%, p=0.033) new-onset worsening (47.3%, p=0.024) in-hospital mortality (38.5%, p=0.017). One-year related rate relapses similar between groups. None treatments were identified as risk protective factors.Conclusion: Our results suggest that is valuable option IE, without differences one-year compared might be considered equally effective.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (30)
CITATIONS (4)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....